Skip to main content

Online Atlas of Stains for NSCLC: PD-L1 IHC 22C3 pharmDx

Image Description
Welcome to the Online Atlas of Stains for NSCLC: PD-L1 IHC 22C3 pharmDx

PD-L1 testing is an integral part of patient care, making your expertise in diagnostic assessment more important than ever. Use the Atlas of Stains to increase your familiarity and confidence in scoring NSCLC specimens stained with PD-L1 IHC 22C3 pharmDx. Tumor Proportion Score (TPS) is the scoring method used for defining
PD-L1 expression in NSCLC specimens.

The Atlas of Stains for NSCLC is a digital repository of NSCLC tissue samples stained with PD-L1 IHC 22C3 pharmDx including:

  • Positive cases that span the full range of PD-L1 expression
  • Negative cases that may demonstrate intrinsic controls (tumor-associated macrophages and immune cell staining)
  • Full specimen staining with H&E, Negative Control Reagent (NCR), and primary antibody for each patient

The viewer interface for the Atlas of Stains for NSCLC features:

  • High-definition, zoomable scans with full-screen and quadrant-view functionality for detailed PD-L1 stain analysis
  • Expert annotations describing areas of interest plus the ability to add your own annotations
  • TPS for each stain, to verify your own assessment
To begin exploring the Atlas, select one of the category of cases from the menu below:
For additional NSCLC scoring guidance and practice, refer to the resources below:

Intended Use

For in vitro diagnostic use.

PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) and melanoma tissue using EnVision FLEX visualization system on Autostainer Link 48.

Non-Small Cell Lung Cancer (NSCLC) PD-L1 protein expression is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity.

PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA® (pembrolizumab). See the KEYTRUDA® product label for expression cutoff values guiding therapy in specific clinical circumstances.